When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

Here are the top 10 best-selling, brand-name drugs of 2024. Bristol Myers Squibb (BMY) and Ono Pharmaceutical’s Opdivo, a treatment for melanoma and other cancers, generated $9.3 billion in ...

Pembrolizumab is currently approved under the brand name Keytruda as a monotherapy and in combination regimens for patients with metastatic or with unresectable, recurrent HNSCC.

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s Keytruda-challenging ivonescimab in combination with several of its antibody-drug conjugates (ADCs).

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the ...